bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Other Events

Item 8.01 Other Events

On December 14, 2016, bluebird bio, Inc. (bluebird) issued a
press release announcing the treatment of the first subject in
the Northstar-2 Study, bluebirds global, multi-center Phase III
study of its LentiGlobin product candidate for the treatment of
patients with transfusion-dependent -thalassemia who do not have
a ^{/ genotype.}

^{The full text of bluebirds press release regarding the
announcement is filed as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.}

^{Item 9.01Financial Statements and Exhibits.}

^{(d) Exhibits}

About bluebird bio, Inc. (NASDAQ:BLUE)

bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

bluebird bio, Inc. (NASDAQ:BLUE) Recent Trading Information

bluebird bio, Inc. (NASDAQ:BLUE) closed its last trading session 00.00 at 68.55 with 844,632 shares trading hands.